Abstract 5564: QLS31901, a novel bifunctional anti-PD-L1/TGF-β fusion protein for treatment of solid tumors
Abstract Immunosuppressive pathway blocking antibodies (e.g., anti-programmed death ligand 1 [PD-L1] antibodies) are effective and feasible cancer therapy, but some patients have poor individual drug responses to this class of drugs. Simultaneous targeting other immunosuppressive pathways is therefo...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 82; no. 12_Supplement; p. 5564 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
15.06.2022
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Immunosuppressive pathway blocking antibodies (e.g., anti-programmed death ligand 1 [PD-L1] antibodies) are effective and feasible cancer therapy, but some patients have poor individual drug responses to this class of drugs. Simultaneous targeting other immunosuppressive pathways is therefore a novel method to enhance the efficacy. While the antitumor activity of bifunctional anti-PD-L1/transforming growth factor-β (TGF-β) fusion protein bintrafusp alfa (M7824) in preclinical studies is well known, clinical studies to date with M7824 have led to limited success. QLS31901 is another bifunctional fusion protein composed of the truncated extracellular domain of the TGF-β receptor II fused to the C-terminus of humanized anti-PD-L1 heavy chain (αPD-L1) with function as a “trap” for all three TGF-β isoforms and the blockage of PD-L1 immunosuppressive pathway. The present study demonstrated its superior antitumor activity over M7824 in a humanized MDA-MB-231 model. Furthermore, toxicology studies of QLS31901 only showed a transient interleukin 6 elevation. There were no other cytokine release and organ toxicity in cynomolgus monkeys. Overall, these data provided a rationale for an expansion cohort study of QLS31901 for the treatment of patients with solid tumors and dual blockade of TGF-β as well as PD-L1 with QLS31901 may be a promising therapy.
Citation Format: Jiahua Jiang, Cuicui Han, Qi Chen, Yun Wu, Xiaodan Yan, Ping Cao. QLS31901, a novel bifunctional anti-PD-L1/TGF-β fusion protein for treatment of solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5564. |
---|---|
AbstractList | Abstract
Immunosuppressive pathway blocking antibodies (e.g., anti-programmed death ligand 1 [PD-L1] antibodies) are effective and feasible cancer therapy, but some patients have poor individual drug responses to this class of drugs. Simultaneous targeting other immunosuppressive pathways is therefore a novel method to enhance the efficacy. While the antitumor activity of bifunctional anti-PD-L1/transforming growth factor-β (TGF-β) fusion protein bintrafusp alfa (M7824) in preclinical studies is well known, clinical studies to date with M7824 have led to limited success. QLS31901 is another bifunctional fusion protein composed of the truncated extracellular domain of the TGF-β receptor II fused to the C-terminus of humanized anti-PD-L1 heavy chain (αPD-L1) with function as a “trap” for all three TGF-β isoforms and the blockage of PD-L1 immunosuppressive pathway. The present study demonstrated its superior antitumor activity over M7824 in a humanized MDA-MB-231 model. Furthermore, toxicology studies of QLS31901 only showed a transient interleukin 6 elevation. There were no other cytokine release and organ toxicity in cynomolgus monkeys. Overall, these data provided a rationale for an expansion cohort study of QLS31901 for the treatment of patients with solid tumors and dual blockade of TGF-β as well as PD-L1 with QLS31901 may be a promising therapy.
Citation Format: Jiahua Jiang, Cuicui Han, Qi Chen, Yun Wu, Xiaodan Yan, Ping Cao. QLS31901, a novel bifunctional anti-PD-L1/TGF-β fusion protein for treatment of solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5564. |
Author | Wu, Yun Jiang, Jiahua Yan, Xiaodan Han, Cuicui Chen, Qi Cao, Ping |
Author_xml | – sequence: 1 givenname: Jiahua surname: Jiang fullname: Jiang, Jiahua – sequence: 2 givenname: Cuicui surname: Han fullname: Han, Cuicui – sequence: 3 givenname: Qi surname: Chen fullname: Chen, Qi – sequence: 4 givenname: Yun surname: Wu fullname: Wu, Yun – sequence: 5 givenname: Xiaodan surname: Yan fullname: Yan, Xiaodan – sequence: 6 givenname: Ping surname: Cao fullname: Cao, Ping |
BookMark | eNqdj8FKAzEYhINUsNU-QuF_ANPm393U6q2o1UMLFXsP6TaBSDYpf7KCr-WD-EwaFPHsaYYZBr4ZsUGIwTA2QTFFlIsZynrBr5pGTpebSlQVl3LenLDhbz7448_YKKUXIYREIYfML_cpk24zlNENPK2fa7wWeAkaQnw1HvbO9qHNLgbtQYfs-PaOr3G2e1jxj3ewffqq4EgxGxfARoJMRufOhAzRQoreHSD3XaR0wU6t9smMf_ScydX97vaRtxRTImPVkVyn6U2hUOWaKtiqYKvva6pQ1v_dfQJ1K1iY |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1158/1538-7445.AM2022-5564 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-7445 |
EndPage | 5564 |
ExternalDocumentID | 10_1158_1538_7445_AM2022_5564 |
GroupedDBID | --- -ET 18M 29B 2WC 34G 39C 476 53G 5GY 5RE 5VS 6J9 AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CITATION CS3 DIK DU5 EBS EJD F5P FRP GX1 IH2 KQ8 L7B LSO OK1 P0W P2P PQQKQ RCR RHF RHI RNS SJN TR2 W2D W8F WH7 WOQ YKV YZZ |
ID | FETCH-crossref_primary_10_1158_1538_7445_AM2022_55643 |
ISSN | 1538-7445 |
IngestDate | Thu Sep 26 17:15:41 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12_Supplement |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-crossref_primary_10_1158_1538_7445_AM2022_55643 |
ParticipantIDs | crossref_primary_10_1158_1538_7445_AM2022_5564 |
PublicationCentury | 2000 |
PublicationDate | 2022-06-15 |
PublicationDateYYYYMMDD | 2022-06-15 |
PublicationDate_xml | – month: 06 year: 2022 text: 2022-06-15 day: 15 |
PublicationDecade | 2020 |
PublicationTitle | Cancer research (Chicago, Ill.) |
PublicationYear | 2022 |
SSID | ssj0005105 |
Score | 4.4805307 |
Snippet | Abstract
Immunosuppressive pathway blocking antibodies (e.g., anti-programmed death ligand 1 [PD-L1] antibodies) are effective and feasible cancer therapy, but... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 5564 |
Title | Abstract 5564: QLS31901, a novel bifunctional anti-PD-L1/TGF-β fusion protein for treatment of solid tumors |
Volume | 82 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwELUKSIgLYhW7fIBTSAqN3QZuZSlrERVFcIuISUWkkiIUc-CzuPIPfBMztptYpUKUS5RaysT1PM3m5wkhmzURiIjvCHePM0hQ2C7DlrdIm4pYh_kCQm6sQzavqqe37Pye35dKnxZrSWaRJ96Hniv5j1ZhDPSKp2RH0GwuFAbgHvQLV9AwXP-k43qEhQqROZxXGeb2rcsbH32v4mQ6ae8t7jpRgr7LlPxgHRP3-si9RAPWPmm4W4fHWwcVpyOxauaorg2J4R7mFHSIJ-F_JI9OJp97ZvenaG4g4lfHtAx6UnvCmtyhjE-361mlhvPEFKfh5kk-FMZPb_zLRMikoBtoe9jKR-6kchcytQsVkOPiF374gG2tMd090ouHjBmDHFRs4FVC9X3TggikLS0urOW1-z9_egSOpxzy93j1pppb8bjdgXvAM-Z8RZUp8SBEMSGKCbWYEMWMkYlKbY8jn_To7KLgF2n-bP5mc3wMxJSHzsYKjKwIpz1Dpk1qQusaZ7OkFKdzZLJpyBfzpNuHG0VB-7QPtm36QBXUqA01WkCtjED7-qAaZNSAjALIaA4y2utQBTKqQbZAeOO4fXjq9mcbvui-KOGvq-QvkvG0l8ZLhDLffxQcMv0IkllYuKAaQJwPQVJc9ePdWrRMvNFkr4z6wCqZKhC6RsazVxmvQ3CZRRtKid-Kem25 |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abstract+5564%3A+QLS31901%2C+a+novel+bifunctional+anti-PD-L1%2FTGF-%CE%B2+fusion+protein+for+treatment+of+solid+tumors&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Jiang%2C+Jiahua&rft.au=Han%2C+Cuicui&rft.au=Chen%2C+Qi&rft.au=Wu%2C+Yun&rft.date=2022-06-15&rft.issn=1538-7445&rft.eissn=1538-7445&rft.volume=82&rft.issue=12_Supplement&rft.spage=5564&rft.epage=5564&rft_id=info:doi/10.1158%2F1538-7445.AM2022-5564&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_1538_7445_AM2022_5564 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7445&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7445&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7445&client=summon |